Compare MIRA & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRA | UG |
|---|---|---|
| Founded | 2020 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 36.5M |
| IPO Year | 2023 | 1995 |
| Metric | MIRA | UG |
|---|---|---|
| Price | $0.89 | $7.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 6.8K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 7.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $10,545,468.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.40 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $5.58 |
| 52 Week High | $2.45 | $8.45 |
| Indicator | MIRA | UG |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 45.74 |
| Support Level | $0.72 | $6.90 |
| Resistance Level | $1.02 | $7.48 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 82.99 | 14.14 |
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.